6-氨基-5-羟基-2-苯基色烯-4-酮 | 92497-96-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 6-氨基-5-羟基-2-苯基色烯-4-酮
• 英文名称: 6-amino-5-hydroxy-2-phenyl-4H-chromen-4-one
• 英文别名: 6-Amino-5-hydroxy-flavon；6-amino-5-hydroxy-2-phenyl-chromen-4-one；6-Amino-5-hydroxy-2-phenyl-chromen-4-on；6-Amino-5-hydroxy-2-phenyl-4H-1-benzopyran-4-one；6-amino-5-hydroxy-2-phenylchromen-4-one
• CAS: 92497-96-6
• 化学式: C₁₅H₁₁NO₃
• 分子量: 253.257
• InChiKey: YTQUFLYEUYMJCT-UHFFFAOYSA-N

物化性质

• 熔点：
  177 °C(Solv: ethanol (64-17-5))
• 沸点：
  477.8±45.0 °C(Predicted)
• 密度：
  1.407±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-氨基-5-羟基-2-苯基色烯-4-酮 在 硫酸 作用下， 生成 5,6-二羟基黄酮
  参考文献：
  名称：

  Iyer; Venkataraman, Proceedings - Indian Academy of Sciences, Section A, 1953, # 37, p. 629,641

  摘要：

  DOI：
• 作为产物：
  描述：

  5-hydroxy-2-phenyl-6-phenylazo-chromen-4-one 在 乙醇 、 溶剂黄146 、 锌 作用下， 生成 6-氨基-5-羟基-2-苯基色烯-4-酮
  参考文献：
  名称：

  Iyer; Venkataraman, Proceedings - Indian Academy of Sciences, Section A, 1953, # 37, p. 629,641

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
  申请人：REMYND NV

  公开号：WO2016083490A1

  公开（公告）日：2016-06-02

  This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。
• α-Glucosidase inhibition of 6-hydroxyflavones. Part 3: Synthesis and evaluation of 2,3,4-trihydroxybenzoyl-containing flavonoid analogs and 6-aminoflavones as α-glucosidase inhibitors
  作者：Hong Gao、Jun Kawabata

  DOI：10.1016/j.bmc.2004.12.010

  日期：2005.3.1

  The SAR studies suggested that the C-ring of baicalein (1) was not necessary for the activity, and validated the importance of 2,3,4-trihydroxybenzoyl structure of 1. Thus, a series of 2,3,4-trihydroxybenzoyi-containing flavonoid analogs were investigated for the alpha-glucosidase inhibitory activity. The results indicated that 5,6,7-trihydroxy-2-phenyl-4-quinolone (2) and 5,6,7-trihydroxyflavanone (4) showed the comparable activity to 1, while 3,5,6,7-tetrahydroxyflavone (7), 5,6,7-trihydroxyisoflavone (8), and 6-hydroxygenistein (9) showed moderate alpha-glucosidase inhibitory activity. In addition, it was found that 6-amino-5,7-dihydroxyflavone (16) was a more potent and specific rat intestinal alpha-glucosidase inhibitor than 1, and showed the comparable activity to acarbose. This is the first report on mammalian intestinal alpha-glucosidase inhibitory activity of 6-aminoflavones. Kinetic studies revealed that 16 inhibited both sucrose- and maltose-hydrolyzing activities of rat intestinal alpha-glucosidase uncompetitively/ (C) 2004 Elsevier Ltd. All rights reserved.
• Sugasawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1936, vol. 56, p. 560; engl. Ref. S. 105
  作者：Sugasawa

  DOI：——

  日期：——
• Iyer; Venkataraman, Proceedings - Indian Academy of Sciences, Section A, 1953, # 37, p. 629,641
  作者：Iyer、Venkataraman

  DOI：——

  日期：——